26155-31-7|酒石酸甲噻嘧啶|Morantel Tartrate|-范德生物科技公司

酒石酸甲噻嘧啶

NMR下载 COA and HPLC MSDS下载
names：
Morantel Tartrate
CAS号：
26155-31-7
MDL Number：
MF(分子式)： C16H22N2O6S MW(分子量)： 220.3315009
EINECS:247-481-5 Reaxys Number:
Pubchem ID:6433951 Brand:BIOFOUNT

酒石酸甲噻嘧啶(26155-31-7,Morantel Tartrate)是3-甲基噻吩酒石酸酯盐的类似物，酒石酸甲噻嘧啶是一种低毒的广谱驱虫药，对某些线虫物种的未成熟和成年阶段有效。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
HCC336920-100mg	100mg	97%	¥ 598.50	¥ 598.50		4-7周	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	酒石酸甲噻嘧啶(26155-31-7,Morantel Tartrate);甲噻嘧啶;摩朗得酒石酸盐;甲噻嘧啶(酒石酸莫仑太尔);甲噻嘧啶酒石酸单水合物;酒石酸莫仑太尔;酒石酸甲噻嘧啶水合物
英文别名	Morantel Tartrate(26155-31-7);Paratect;Banminth II;Morantel (tartrate)
CAS号	26155-31-7
Inchi	InChI=1S/C12H16N2S.C4H6O6/c1-10-6-9-15-11(10)4-5-12-13-7-3-8-14(12)2;5-1(3(7)8)2(6)4(9)10/h4-6,9H,3,7-8H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
InchiKey	GGXQONWGCAQGNA-LREBCSMRSA-N
分子式 Formula	C16H22N2O6S
分子量 Molecular Weight	220.3315009
溶解度Solubility	Methanol (Slightly), Water (Slightly)
性状	白色或类白色结晶性粉末
储藏条件 Storage conditions	存放在阴凉干燥处，短期（数天至数周）在0-4℃，长期（数月至数年）在-20℃。

酒石酸甲噻嘧啶(26155-31-7,Morantel Tartrate)毒性测试：

生物	测试类型	路线	报告剂量（标准化剂量）	影响	参考
rat	LD50	oral	926 mg/kg (926 mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD; BEHAVIORAL: ATAXIA; SKIN AND APPENDAGES (SKIN): HAIR: OTHER	Australian Veterinary Journal., 46(297), 1970 [PMID:5455592]
rat	LD50	skin	>5 gm/kg (5000 mg/kg)		Nippon Noyaku Gakkaishi. Journal of the Pesticide Science Society of Japan., 17(S323), 1992
rat	LD50	intraperitoneal	37500 ug/kg (37.5 mg/kg)		Nippon Noyaku Gakkaishi. Journal of the Pesticide Science Society of Japan., 17(S323), 1992
rat	LD50	subcutaneous	38800 ug/kg (38.799999999999997 mg/kg)		Nippon Noyaku Gakkaishi. Journal of the Pesticide Science Society of Japan., 17(S323), 1992
mouse	LD50	skin	>5 gm/kg (5000 mg/kg)		Nippon Noyaku Gakkaishi. Journal of the Pesticide Science Society of Japan., 17(S323), 1992

酒石酸甲噻嘧啶(26155-31-7,Morantel Tartrate)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

Morantel Tartrate(26155-31-7) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:酒石酸甲噻嘧啶(26155-31-7,Morantel Tartrate),酒石酸甲噻嘧啶试剂,酒石酸甲噻嘧啶抑制剂,酒石酸甲噻嘧啶杂质,酒石酸甲噻嘧啶的作用,酒石酸甲噻嘧啶的纯度,酒石酸甲噻嘧啶的外观,酒石酸甲噻嘧啶的性质,酒石酸甲噻嘧啶的合成,酒石酸甲噻嘧啶的生产,酒石酸甲噻嘧啶的厂家

产品说明	酒石酸甲噻嘧啶(26155-31-7,Morantel Tartrate)是3-甲基噻吩酒石酸酯盐的类似物，酒石酸甲噻嘧啶是一种低毒的广谱驱虫药
Introduction	Morantel Tartrate (26155-31-7,酒石酸甲噻嘧啶) is an analogue of 3-methylthiophene tartrate. Methypyridine tartrate is a low-toxic, broad-spectrum insect repellent
Application1
Application2
Application3

警示图
危险性	warning
危险性警示	Not available
安全声明	H303+H313+H333
安全防护	P264+P280+P305+P351+P338+P337+P313
备注	实验过程中防止吸入、食入，做好安全防护

Effectiveness of morantel tartrate and naphthalophos against levamisole resistantOstertagia in sheep(Veterinary Science Communications,1979)

Larval paralysis as an in vitro assay of levamisole and morantel tartrate resistance inOstertagia(Veterinary Science Communications,1979)

Zum übertritt von Morantel in Kuhmilch nach Applikation der Retardform ?Paratect Bolus” (Pfizer)( Zeitschrift für Lebensmittel-Untersuchung und Forschung,1987)

Efficacy of morantel sustained release trilaminate bolus against gastrointestinal nematodes in grazing dairy calves in Kenya( Tropical Animal Health and Production,1996)

The efficacy of anthelmintics against third stage larvae ofAncylostoma caninum inMastomys natalensis(Zeitschrift für Parasitenkunde,1978)

Chemotherapy of Gastrointestinal Nematodiasis in Ruminants
Abstract:Effective control of gastrointestinal nematodes in ruminants must be based on a thorough knowledge of the epidemiology of these parasites. In some instances gastrointestinal nematodes can be controlled by good pasture management (Borgsteede and Kloosterman 1977; Eysker and Hendrikx 1977). Other systems depend on frequent treatments with short intervals. Most control systems, however, are based on both pasture management and strategic or tactical treatments (see Chap. 3, this volume).

Repositioning of new potential schistosomicidal drugs using chemogenomic strategy
Background:Schistosomiasis remains a severe problem of public health in developing countries [1]. Several reports show that praziquantel, the drug of choice for treating schistosomiasis, can select Schistosoma mansoni strains resistant to the drug. Thus, developing new drugs against this parasitosis is a highly desirable goal [2]. In this context, enzymes involved in energetic metabolism could represent attractive drug targets for novel anti-schistosome chemotherapies [3, 4]. We report a chemogenomic strategy for identification of approved drugs that may be able to interfere with energetic metabolism of the Schistosoma mansoni.
Methods:The chemogenomic study was performed on a list containing 734 genes involved in oxidative phosphorylation (n = 45); nitrogen metabolism (n = 642); glycolysis (n = 11); citrate cycle (n = 10); and others (n = 26). Next, it was obtained from the GeneDB S. mansoni genome database individual information for genes (amino acid sequence in FASTA format, product name, and biological process). Each of these protein sequences was treated as a potential drug target and used to screen three freely available databases (DrugBank, STITCH 3.1, and TTD) based in the concept of the target sequence similarity. The targets with E-value score ≤ 10-5 and score ≥ 0.7 were considered for further analyses.
Results and conclusions:We were able to identify several drugs that are expected to interact with 6 targets involved in nitrogen metabolism (carbonic anhydrase II and carbonic anidrase), citrate cycle (succinate dehydrogenase), oxidative phosphorylation (ATP synthase delta chain and NADH-ubiquinone oxidoreductase mitochondrial precursor), and glutamate metabolism (glutaminase). One of these targets was associated with thiabendazole, whose activity has been previously evaluated against S. mansoni. [5]. However, 18 drugs were predicted to have activity against other targets and have never been evaluated against schistosoma parasites (e.g., acetazolamide, doxorubicin, morantel tartrate, axantel pamoate, thiabendazole, and menthol). Our next step is to experimentally screen these drugs against S. mansoni. Being a cost and time saving route, drug repositioning is expected to accelerate the discovery of new anti-schistosome chemotherapies.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开